| Event: 7 May the company announced that subsidiary | | | | Large population base, the market is vast. According |
| Tasly Ginna Biotechnology (Tianjin) Co., Ltd. Drugs | | | | to the 2002 World Health Organization (WHO) |
| "influenza virus subunit vaccine" received | | | | released data, the number of influenza cases per |
| SFDA approval document issued by the drug | | | | year worldwide is about 600 million -12 million |
| registration, the approval date of April 29, 2009 . The | | | | (incidence rate of about 10% -20%), according to |
| approved products include: 0.5mL bottle of subunit | | | | statistics, in 2004 the world's 1.3 billion influenza |
| influenza vaccine (Xilin bottle) and an annual output of | | | | vaccine market U.S. dollars, accounting for 14% of |
| 1.2 million bottles of 0.5mL each subunit influenza | | | | global vaccine sales are expected to reach 3.7 billion |
| vaccine (prefilled syringe packaging) annual output of | | | | by 2010. The current global influenza vaccine |
| 2.8 million. | | | | production is only 2.8-3.0 million doses per year, only |
| Investment Highlights: accelerating the pace of | | | | 14% of the population to meet global demand, while |
| industrialization of biotechnology companies enrich | | | | only 2% of our coverage, our country has a |
| product mix. Influenza virus subunit vaccine for the | | | | population of more than 1.3 billion (end 2007), the |
| prevention of use of biological products, to obtain the | | | | proportion of the world 20%, we believe that a large |
| registration document of approval for the | | | | population base and coverage of low-highlight factors |
| company's bio-pharmaceutical industry to speed | | | | will bring a broad market space. |
| up the process and to further enrich the product mix | | | | Continue to improve the industrial chain of modern |
| is important, while the occasion of approved vaccine | | | | medicine. Competitive products Danshen Dropping Pill |
| crisis underlines the company's strong R & | | | | FDA phase II clinical trials have been completed, still |
| D capabilities and public relations capacity. In addition | | | | need to wait for the results of clinical summary |
| the company Pro-uk (urokinase) qualified | | | | report, the project's success not only for the |
| fermentation harvest index significantly improved, in | | | | company, and even China for the Chinese medicine |
| April 2009 the project has received national drug | | | | Chinese medicine sector has epoch-making impact, so |
| review center review comments and additional | | | | has the extraordinary significance. In addition, we |
| information in the report completed in August. | | | | believe that companies may follow-up there will be |
| Domestic only two companies approved. Subunit | | | | other species pass through the only FDA. Shaanxi |
| vaccine is the use of a surface structure of microbial | | | | Tasly Pharmaceutical Co., Ltd. Shangluo Salvia plant |
| components (antigen) made of nucleic acid, can | | | | source drug base in 2004 by the State Food and |
| induce the body to produce antibodies to the | | | | Drug Administration certified the first eight |
| vaccine, is the third generation of the previous two | | | | enterprises through GAP certified company, GAP |
| generations of influenza vaccine (whole virus influenza | | | | drug source base for the company's product |
| vaccine and influenza split vaccine) compared to have | | | | cost and quality lock . Shaanxi Tasly in January 2007 |
| a good side effect of protective antigen and small | | | | passed the GMP certification, and production in the |
| features present, only two pressure units of influenza | | | | same year in July, can produce more than 800 |
| vaccine companies get approval document, and | | | | chemicals regulation of Chinese Herbal Medicine, |
| another is a subsidiary of Neptune Neptunus | | | | Chinese Herbal Medicine will become another profit |
| Bioengineering Interlong (May 25, 2006 granted), | | | | growth. We believe that Yangxueqingnao particles |
| because of technical difficulties as well as | | | | become new growth points, the next two years will |
| Novartis's currently only a handful of U.S. Chiron | | | | be to maintain sales growth. |
| and other companies to realize industrialization. In | | | | Earnings forecast and investment advice. We expect |
| addition Neptunus Bioengineering and GlaxoSmithKline | | | | the company's EPS 09-11 years were 0.65 |
| Glaxo has just set up a joint venture company is also | | | | yuan, 0.81 yuan, 1.10 yuan, target price of 33.21 yuan, |
| prepared to set foot Shike Hai Wang influenza | | | | 41 times in 2010 relative PE, maintaining a |
| subunit vaccine and split vaccine development and | | | | "buy" investment rating. |
| production. | | | | |